Neurocrine Biosciences Inc (NBIX)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Neurocrine Biosciences Inc (NBIX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012213
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Neurocrine Biosciences Inc (Neurocrine) discovers, develops and commercializes pharmaceutical products for the treatment of neurologic, psychiatric and endocrine related diseases and disorders. Its lead product, Ingrezza (valbenazine) capsule is a US FDA approved selective vesicular monoamine transporter 2 inhibitor for the treatment of adults with tardive dyskinesia (TD). Its other major pipeline products include elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis and uterine fibroids and opicapone, a catechol-O-methyltransferase inhibitor (COMT inhibitor) intended for adult patients with Parkinson’s disease. It also develops drug candidates for the treatment of essential tremor and classic congenital adrenal hyperplasia. The company has development and licencing partnerships with AbbVie Inc, BIAL–Portela & CA, S.A. and Mitsubishi Tanabe Pharma. Neurocrine is headquartered in San Diego, California, the US.

Neurocrine Biosciences Inc (NBIX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Neurocrine Biosciences Enters into Licensing Agreement with Bial 10
Neurocrine Biosciences Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 11
Equity Offering 12
Neurocrine Biosciences Raises USD288 Million in Public Offering of Shares 12
Neurocrine Biosciences Completes Public Offering Of Shares For US$142 Million 14
Neurocrine Biosciences Completes Over-allotment Option Of Underwritten Public Offering For US$88.5 Million 16
Debt Offering 18
Neurocrine Biosciences Raises USD517.5 Million in Private Placement of 2.25% Notes Due 2024 18
Neurocrine Biosciences Inc – Key Competitors 20
Neurocrine Biosciences Inc – Key Employees 21
Neurocrine Biosciences Inc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Nov 01, 2017: Neurocrine Biosciences Reports Third Quarter 2017 Results 23
Aug 03, 2017: Neurocrine Biosciences Reports Second Quarter 2017 Results 25
May 09, 2017: Neurocrine Biosciences Reports First Quarter 2017 Results 27
Feb 14, 2017: Neurocrine Biosciences Reports Year-End 2016 Results and Provides Investor Update for 2017 30
Nov 02, 2016: Neurocrine Biosciences Reports Third Quarter 2016 Results 33
Aug 03, 2016: Neurocrine Biosciences Reports Second Quarter 2016 Results 36
May 05, 2016: Neurocrine Biosciences Reports First Quarter 2016 Results 38
Feb 11, 2016: Neurocrine Biosciences Reports Year-End 2015 Results and Provides Investor Update for 2016 40
Corporate Communications 42
Nov 20, 2017: Neurocrine Biosciences Appoints Matt Abernethy as Chief Financial Officer 42
Jan 06, 2017: Neurocrine Biosciences Announces the Appointment of David-Alexandre Gros M.D. President and Chief Operating Officer 43
Dec 21, 2016: Neurocrine Biosciences Announces Chief Financial Officer Timothy P. Coughlin to Step Down 44
May 20, 2016: Neurocrine Biosciences Announces the Retirement of W. Thomas Mitchell from the Board of Directors 45
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Neurocrine Biosciences Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Neurocrine Biosciences Enters into Licensing Agreement with Bial 10
Neurocrine Biosciences Enters into Licensing Agreement with Mitsubishi Tanabe Pharma 11
Neurocrine Biosciences Raises USD288 Million in Public Offering of Shares 12
Neurocrine Biosciences Completes Public Offering Of Shares For US$142 Million 14
Neurocrine Biosciences Completes Over-allotment Option Of Underwritten Public Offering For US$88.5 Million 16
Neurocrine Biosciences Raises USD517.5 Million in Private Placement of 2.25% Notes Due 2024 18
Neurocrine Biosciences Inc, Key Competitors 20
Neurocrine Biosciences Inc, Key Employees 21
Neurocrine Biosciences Inc, Subsidiaries 22

★海外企業調査レポート[Neurocrine Biosciences Inc (NBIX)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The People’s Insurance Company (Group) of China Limited:戦略・SWOT・企業財務分析
    The People's Insurance Company (Group) of China Limited - Strategy, SWOT and Corporate Finance Report Summary The People's Insurance Company (Group) of China Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the compan …
  • Delta Air Lines Inc:戦略・SWOT・企業財務分析
    Delta Air Lines Inc - Strategy, SWOT and Corporate Finance Report Summary Delta Air Lines Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • ARCA biopharma Inc (ABIO):企業の財務・戦略的SWOT分析
    Summary ARCA Biopharma Inc (ARCA), formerly Nuvelo Inc is a developer of genetically targeted therapies for cardiovascular diseases. The company’s product candidate include Gencaro, a mild vasodilator and investigational pharmacologically unique beta-blocker that is being developed for the treatment …
  • Evergreen Packaging Inc:企業の戦略・SWOT・財務情報
    Evergreen Packaging Inc - Strategy, SWOT and Corporate Finance Report Summary Evergreen Packaging Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • ITT Inc.:企業のM&A・事業提携・投資動向
    ITT Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's ITT Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …
  • Virginia Electric and Power Company:発電所・企業SWOT分析
    Virginia Electric and Power Company – Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • KT&G Corp:企業の戦略・SWOT・財務情報
    KT&G Corp - Strategy, SWOT and Corporate Finance Report Summary KT&G Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Karoon Gas Australia Ltd (KAR):企業の財務・戦略的SWOT分析
    Karoon Gas Australia Ltd (KAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Dick’s Sporting Goods Inc:戦略・SWOT・企業財務分析
    Dick’s Sporting Goods Inc - Strategy, SWOT and Corporate Finance Report Summary Dick’s Sporting Goods Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Phosphagenics Ltd:企業の戦略・SWOT・財務情報
    Phosphagenics Ltd - Strategy, SWOT and Corporate Finance Report Summary Phosphagenics Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Casino Guichard-Perrachon SA:戦略・SWOT・企業財務分析
    Casino Guichard-Perrachon SA - Strategy, SWOT and Corporate Finance Report Summary Casino Guichard-Perrachon SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • China Tontine Wines Group Limited:企業の戦略・SWOT・財務情報
    China Tontine Wines Group Limited - Strategy, SWOT and Corporate Finance Report Summary China Tontine Wines Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Guardant Health Inc:医療機器:M&Aディール及び事業提携情報
    Summary Guardant Health Inc (Guardant Health) is a non-invasive cancer diagnostics company that commercializes genomic liquid biopsy. The company develops proprietary digital sequencing technology used to detect individual genomic alterations. It offers Guardant360, a tool for early cancer detection …
  • CohBar Inc (COB.U):企業の財務・戦略的SWOT分析
    Summary CohBar Inc (CohBar) is a developer of mitochondria based therapeutics. The company develops a class of drugs to treat a wide range of diseases associated with aging and metabolic dysfunction such as non-alcoholic steatohepatitis, obesity, type 2 diabetes, cancer, cardiovascular disease and C …
  • Finning International Inc (FTT):企業の財務・戦略的SWOT分析
    Finning International Inc (FTT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Isofol Medical AB (ISOFOL):製薬・医療:M&Aディール及び事業提携情報
    Summary Isofol Medical AB (Isofol) is a clinical stage pharmaceutical company that develops folate-based therapies for the treatment of cancer patients. The company offers clinical lead candidate Modufolin, a novel folate-based therapy, which is developed to increase the efficacy and reduce the side …
  • Vertex Pharmaceuticals Inc (VRTX):製薬・医療:M&Aディール及び事業提携情報
    Summary Vertex Pharmaceuticals Inc (Vertex) is a biotechnology company that carries out the discovery, development and commercialization of transformative drugs for the treatment of serious and life-threatening diseases. The company product portfolio includes Orkambi (ivacaftor/lumacaftor) and Kalyd …
  • Burke-Divide Electric Cooperative Inc:企業の戦略的SWOT分析
    Burke-Divide Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • Datalogic SpA (DAL):企業の財務・戦略的SWOT分析
    Datalogic SpA (DAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Fonar Corp (FONR):企業の財務・戦略的SWOT分析
    Summary Fonar Corp (Fonar) is a medical device company that develops and manufacturers magnetic resonance imaging (MRI) scanners. The company provides products such as upright MRI, Fonar 360 and the open sky MRI. Fonar upright MRI is equipped with its MRI–compatible motorized patient handling system …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆